Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 6,000,000 shares, a growth of 6.0% from the December 31st total of 5,660,000 shares. Approximately 31.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 250,800 shares, the days-to-cover ratio is presently 23.9 days.

Analyst Upgrades and Downgrades

DNTH has been the topic of several recent research reports. Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. TD Cowen started coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They set a "buy" rating on the stock. Oppenheimer lifted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, November 11th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $46.43.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DNTH. R Squared Ltd bought a new position in Dianthus Therapeutics in the 4th quarter valued at $26,000. Quest Partners LLC boosted its stake in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after purchasing an additional 1,124 shares during the period. KBC Group NV bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $35,000. AlphaQuest LLC increased its stake in Dianthus Therapeutics by 273.1% in the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock worth $91,000 after buying an additional 3,072 shares during the period. Finally, SG Americas Securities LLC increased its stake in Dianthus Therapeutics by 9.2% in the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock worth $210,000 after buying an additional 814 shares during the period. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock traded up $0.09 during trading on Friday, hitting $23.05. The stock had a trading volume of 232,332 shares, compared to its average volume of 260,921. The stock has a market cap of $682.21 million, a PE ratio of -9.22 and a beta of 1.72. Dianthus Therapeutics has a 12 month low of $18.34 and a 12 month high of $33.77. The firm's fifty day simple moving average is $23.04 and its 200-day simple moving average is $25.82.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.